Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed meningioma~* Recurrent or progressive disease after prior surgical resection~* Measurable disease by contrast-enhanced MRI~* Multifocal disease allowed~* No evidence of intratumor hemorrhage on pretreatment diagnostic imaging~  * Stable postoperative grade 1 hemorrhage allowed~* No peripheral edema or central or systemic fluid collections ≥ grade 2 (e.g., pericardial effusion, pulmonary effusion, ascites)~PATIENT CHARACTERISTICS:~* Karnofsky performance status 70-100%~* Absolute neutrophil count \> 1,500/mm³~* Hemoglobin \> 9 g/dL~* Platelet count \> 100,000/mm³~* Potassium normal\*~* Calcium normal\*~* Magnesium normal\*~* Phosphorus normal\*~* alanine aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 times upper limit of normal (ULN)~* Bilirubin \< 1.5 times ULN~* Creatinine \< 1.5 times ULN OR creatinine clearance \> 50 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No excessive risk of bleeding, as defined by stroke within the past 6 months~* No active systemic bleeding (i.e., gastrointestinal bleeding or gross hematuria)~* No history of central nervous system (CNS) or intraocular bleeding or septic endocarditis~* No concurrent severe and/or uncontrolled medical disease, including any of the following:~  * Uncontrolled diabetes~ * Congestive cardiac failure~ * Myocardial infarction within the past 6 months~ * Poorly controlled hypertension~ * History of labile hypertension~ * History of poor compliance with antihypertensive regimen~ * Chronic renal disease~ * Active uncontrolled infection requiring intravenous antibiotics~* No acute or chronic liver disease (i.e., hepatitis, cirrhosis)~* No HIV positivity~* No impairment of gastrointestinal function or disease that may significantly alter the absorption of imatinib mesylate, including any of the following:~  * Ulcerative disease~ * Uncontrolled nausea~ * Vomiting~ * Diarrhea~ * Malabsorption syndrome~ * Bowel obstruction~ * Inability to swallow tablets~* No other malignancy within the past 5 years except basal cell skin cancer or cervical carcinoma in situ NOTE: \*Unless correctable with supplements~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior therapy~* More than 1 week since prior tumor biopsy~* More than 2 weeks since prior surgical resection~* Prior hydroxyurea allowed provided patient has not had progressive disease or toxicity \> grade 3~* No prior imatinib mesylate or other platelet-derived growth factor-directed therapy~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)\*~  * Chemotherapeutic agents such as etoposide that are normally given at shorter intervals allowed even if \< 4 weeks from last prior dose of chemotherapy~* At least 4 weeks since prior radiotherapy\*~* At least 1 week since prior biological, immunotherapeutic, or cytostatic drugs~* At least 2 weeks since prior investigational drugs~* No concurrent warfarin NOTE: \*Unless there is unequivocal evidence of tumor progression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib mesylate+hydroxyurea (Type: EXPERIMENTAL): All patients receive imatinib mesylate and hydroxyurea orally on a daily, continuous basis. Dosing of imatinib mesylate is adjusted for patients who are also receiving p450-inducing anti-epileptic drugs.

Based on this trial design, predict the completion outcome and termination type (if applicable).